Literature DB >> 15031616

Growth and metabolic control during puberty in girls with X-linked hypophosphataemic rickets.

Etienne Sochett1, Andrea S Doria, Flavia Henriques, Sang Whay Kooh, Alan Daneman, Outi Mäkitie.   

Abstract

OBJECTIVE: X-linked hypophosphataemic rickets (XLH) results in defective bone mineralization and impaired growth. Treatment with oral phosphate (Pi) and calcitriol improves but does not normalize growth. This study assessed whether pubertal growth and metabolic control contribute to the height deficit.
METHODS: Study included patients with XLH who were treated with Pi-calcitriol from diagnosis to adult height; their hospital records, biochemistry and radiographs were reviewed.
RESULTS: Six females with XLH were included. Their mean peak height velocity and total height gain during puberty were nearly normal despite deteriorating metabolic control.
CONCLUSIONS: In treated girls with XLH, the pubertal growth is nearly normal despite suboptimal metabolic control. The major height loss occurs prior to puberty and is not recovered during the pubertal growth spurt. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15031616     DOI: 10.1159/000077401

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  6 in total

1.  Growth in X-linked hypophosphatemic rickets.

Authors:  Gema Ariceta; Craig B Langman
Journal:  Eur J Pediatr       Date:  2006-12-14       Impact factor: 3.183

Review 2.  A clinician's guide to X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Ingrid A Holm; Suzanne M Jan de Beur; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2011-05-02       Impact factor: 6.741

Review 3.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

Review 4.  Hypophosphatemia and growth.

Authors:  Fernando Santos; Rocío Fuente; Natalia Mejia; Laura Mantecon; Helena Gil-Peña; Flor A Ordoñez
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

5.  Identification of a Novel Missense Mutation of the PHEX Gene in a Large Chinese Family with X-Linked Hypophosphataemia.

Authors:  Yanting Yang; Yuanda Wang; Ying Shen; Mohan Liu; Siyu Dai; Xiaodong Wang; Hongqian Liu
Journal:  Front Genet       Date:  2022-02-17       Impact factor: 4.599

Review 6.  Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.

Authors:  Claudia Maria Jurca; Oana Iuhas; Kinga Kozma; Codruta Diana Petchesi; Dana Carmen Zaha; Marius Bembea; Sanziana Jurca; Corina Paul; Alexandru Daniel Jurca
Journal:  Genes (Basel)       Date:  2022-08-04       Impact factor: 4.141

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.